 95:1925-1932.) 
The association in children of congenital myopathy with nonprogressive weakness was first described by Brooke in 1973 (1) and termed congenital fiber type disproportion myopathy (CFTDM).' Since then additional case stories of children with CFTDM have been reported by several authors (2, 3) . The clinical picture is characterized by weakness and hypotonia beginning at or shortly after birth, delayed milestones, and in some cases skeletal deformities similar to those seen in other congenital myopathies (2) . Some patients may have delayed onset with mild symptoms, mainly muscle pain (3). In some families, studies of affected siblings suggest an autosomal recessive pattern of inheritance (4) . Other studies have shown parental involvement pointing to an autosomal dominant mode of inheritance (5, 6) . The diagnosis is established by morphological examination of skeletal muscle, which shows a predominance (> 55%) of small type 1 (slow-twitch oxidative) muscle fibers, at least 12% smaller than type 2 fibers, and normal or hypertrophied type 2 (fast-twitch glycolytic) fibers in the absence of other obvious histologic abnormalities (1) . An excess of type 2A (fast-twitch oxidative and glycolytic) hypertrophied fibers (1, 7) or type 2B (fast-twitch glycolytic) hypertrophied fibers (1, 2) has been noticed in some but not all cases (8, 9) . The pathogenesis of the muscle disorder is unknown. Generally, the prognosis is good, with most patients showing improvement with age, although some residual motor impairment often persists. In rare cases, however, there is a progressive muscle weakness, recurrent respiratory tract infections, and respiratory failure necessitating continuous assisted ventilation (7) . Morphologic studies of biopsied muscles are necessary to obtain a final diagnosis (10) .
In this study we describe a family of five members, parents and three sons, of whom both the oldest and the youngest sons have CFTDM and insulin-resistant diabetes mellitus. To characterize the whole-body insulin sensitivity of the parents and of the oldest son affected with CFTDM, we have applied the euglycemic hyperinsulinemic clamp technique in combination with indirect calorimetry. Moreover, we have studied several aspects of insulin-stimulated glucose metabolism in muscle biopsies from the same individuals. 
Methods
Subjects and study design. The probands were referred to the University Hospital in Copenhagen for evaluation of muscle disease and short stature. Clinical data of the probands and their family are presented in Table I . The two probands, brothers at 15 and 8 yr of age, were born of nonconsanguineous healthy parents at term following uncomplicated pregnancies and deliveries. Birth weights/lengths were 2,140 g/48 cm and 1,850 g/48 cm in the oldest and youngest probands, respectively. Both siblings had delayed milestones and muscle weakness. At the age of -18 mo, they were both able to walk alone; however, they were not able to crawl or rise before the age of -3 yr. At the age of 6 yr, both probands were diagnosed as having CFTDM. Muscle biopsies from the children showed 74% small type 1 fibers with a diameter of 16 jum (SD 3 ttm) and 26% type 2 fibers with a diameter of 22 ym (SD 2 , um) . No nemaline bodies were seen. Electromyelograms were normal in both boys, and both have a normal karyotype. Physical examination revealed universal muscle hypotrophy, and both probands were very hairy. No skin pigmentations or acanthosis nigricans was seen. The probands had normal fasting levels of serum thyroid-stimulating hormone, thyroxine, glucagon, and insulin-like growth factor-1, and 24-h urinary excretion of cortisol and growth hormones was likewise normal. Glucosuria and postprandial hyperglycemia were discovered by chance at the age of 13 yr in proband 1 and at 6 yr in proband 2. None of the boys had at that time any symptoms of hyperglycemia. They had normal fasting plasma glucose levels of 5.1 and 4.2 mmol/liter, respectively, but the 2-h plasma glucose concentrations during a 1.75 g/kg body weight oral glucose tolerance test (OGTT) showed diabetes mellitus in the oldest proband, with a plasma glucose of 15.2 mmol/ liter and glucose intolerance in the youngest proband, with a plasma glucose of 8.8 mmol/liter. Both had pronounced hyperinsulinemia at the time of the first OGTT, with fasting serum insulin levels of 1,400 pmol/liter. The patients were prescribed a diabetes diet and followed regularly in the outpatient clinic; after 1 yr, the OGTT was repeated with similar results. The probands were now referred to Steno Diabetes Center for further evaluation and treatment. Late onset, non-insulindependent diabetes mellitus (NIDDM) was known on the maternal site of the family (the probands' great-grandmother and a sister to the grandmother had NIDDM).
Both parents (mother, 37 yr; father, 41 yr) and proband 1 volunteered for studies of whole-body glucose and lipid metabolism (clamp) as well as studies of in vitro muscle metabolism. The results of the clamp study, including muscle biopsies, were compared with those of six healthy control subjects (Table I) with normal fasting plasma glucose (5.3+0.2 mmol/liter), normal blood pressure, and no family history of diabetes. None of the participants in the study suffered from liver or kidney diseases, as evaluated by clinical and standard laboratory examinations, and none of them were taking any medication during the investigation. The participants refrained from physical exercise and any major physical activity for 72 h before the examination. Before entry into the study, the purpose and risks of the experimental protocol were carefully explained to all of the volunteers, and their informed consent was obtained. The protocol was approved by the local Ethical Committee and was in accordance with the Helsinki II Declaration.
OG7T. All five family members had a standard (1.75 g/kg body weight in the children and 75 g in adults) OGTT after a 10-h overnight fast. Venous blood samples were drawn at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of serum insulin, serum C-peptide, and plasma glucose. Moreover, serum proinsulin levels were measured at 0, 60, and 120 min.
Euglycemic hyperinsulinemic clamp. Each clamp lasted for 6 h: a 2-h basal period followed by a 4-h hyperinsulinemic glucose clamp (2 mU insulin/kg/min) in combination with indirect calorimetry, infusion of tritiated glucose, and a muscle biopsy at the end of each study period. Details of the clamp technique have been described previously (1 1, 12) .
Glucose disposal. Total glucose disposal rate was calculated from the concentrations of plasma tritiated glucose and plasma glucose using Steele's non-steady-state equations (13) . In these calculations, the distribution volume of glucose was taken as 200 ml/kg body weight and the pool fraction as 0.65. Total peripheral glucose uptake was corrected for urinary glucose loss.
Glucose and lipid oxidation. Indirect calorimetry was performed using the flow-through canopy gas analyzer system (Deltatrac Metabolic Monitor; Datex, Helsinki, Finland). Rates of oxidation were calculated from Frayn's equation (14) . The nonoxidative glucose metabolism was calculated as the difference between total glucose disposal rate and glucose oxidation, as determined by indirect calorimetry.
Muscle biopsies. Percutaneous muscle biopsies (-400 mg) were obtained under local anesthesia (1% lidocaine without epinephrine) from the vastus lateralis muscle -20 cm above the knee, using a modified Bergstrom needle (Stille-Werner, Copenhagen, Denmark The coefficient of variation of the method is 0.10 (n = 10 separate determinations in triplet). Preparation ofanti-GS antibody and GS immunoblotting. Antibody preparation and immunoblotting were performed as described in detail earlier (12) . Anti-GS antibody was produced against 9 determined by the standard curve of total GS protein using a Shimadzu CS 9000 (Shimadzu Corp., Tokyo, Japan) flying spot densitometer. Studies of the immunoreactivity of GS in muscle specimens from the participants were run at the same time. When six different samples from the same muscle biopsy were analyzed, the coefficient of variation was 0.11 for GS protein.
Determination of GS activity in muscle. Extraction from muscle samples, assays for GS activity, and analysis of protein content in muscle preparations were performed as described previously (16) . GS activity was assayed in duplicate in the absence or presence of seven concentrations (0-6.7 mmol/liter) of glucose-6-phosphate (G6P). Total activity refers to the GS activity in the presence of a saturating concentration of G6P (6.7 mmol/liter). The (FV) were calculated as GS activity in the presence of subsaturating levels of G6P divided by GS activity in the presence of 6.7 mmol/liter G6P. The concentration of G6P giving half-maximal stimulation of the GS (A0.5 for GS) was calculated using a Hill plot. The inter-assay coefficients of variation were 0.12 for A0.5 and 0.13 for total GS, (n = 10 separate experiments).
To exclude any influence of day-to-day variation, muscle samples from the participants were prepared and analyzed for GS mRNA and protein levels as well as for GS enzyme activity at the same time.
Other analytical procedures. Glucose in plasma and in urine was measured by a hexokinase method (17) . Intact insulin in serum was measured applying'an ELISA ( 18) . The method uses two murine mAbs that bind to two different epitopes on the insulin molecule. The immunoassay is specific, and no proinsulin is detected by the assay. Serum Cpeptide and serum proinsulin were analyzed by RIA and ELISA techniques, respectively (19) (20) (21) . For measurement of serum values of insulin, proinsulin, and C-peptide, the detection limit and coefficient of variations were 5 pmol/liter and 0.09, 1.2 pmol/liter and 0.09, and 60 pmol/liter and 0.08, respectively. HbAic (glycosylated hemoglobin) was measured by an HPLC method (normal range 4.1-6.1%). Tritiated glucose in plasma was analyzed as described previously (22) . Free fatty acids (FFAs) in plasma were determined by the method of Itaya and Michio (23).
Results
Characterization ofsubjects. As seen in Table II , fasting serum insulin levels were severely increased in the CFTDM patients when compared with the parents, the healthy brother, and the control subjects (control subjects, 67±7 pmol/liter). It also appears from the table that the glucose-tolerant father was relatively insulin resistant, as reflected by his fasting hyperinsulinemia. The ratio of fasting serum insulin/C-peptide levels was severely increased in both probands (proband 1, 131 %; proband 2, 174%) and to a lesser extent in the father (57%) when compared with the other family members (unaffected brother, 21%; mother, 23%) and the control subjects (10±1%). Thus, it seems likely that the increase in serum insulin in the probands and the father was in part associated with a substantial decrease in insulin clearance.
The increased serum insulin levels were not explained by inappropriately high levels of proinsulin, since the two-site immunoassay used does not measure human proinsulin. This was further confirmed by measuring serum proinsulin levels during the OGTT at time 0, 60 min, and 120 min. It appears, however, that the absolute levels of serum proinsulin were increased in the two boys with CF1DM when compared with both parents and their unaffected brother (Table II) . However, calculating the fasting proinsulin/insulin ratios, no increase was found in the probands compared with the other family members (proband 1, 4.5%; proband 2, 3.7%; unaffected brother, 6.9%; mother, 8.9%; father, 2.7%). Thus, the insulin resistance in the probands does not seem to cause an increased proportion of proinsulin to be secreted.
It is also seen from Table H that both probands were diabetic in accordance to World Health Organization criteria.
Glucose and lipid metabolism in vivo. During the basal period of the clamp study, the glucose disposal rate in proband 1 was increased when compared with that of the control group (104 and 74±3 mg/m2/min, respectively) (Fig. 1) . The increased glucose disposal rate was due to both an increased glucose oxidation rate (67 and 56±4 mg/m2/min, respectively) and an increased nonoxidative glucose metabolism (37 versus 18±5 mg/m2/min, respectively). Basal glucose disposal rate in the parents was comparable to that of the control group (mother, 74 mg/m2/min; father, 69 mg/m2/min). However, basal nonoxidative glucose metabolism was severely decreased in the -father (3 mg/m2/min), whereas the glucose oxidation rate was increased (66 mg/m2/min). In the mother, both basal glucose oxidation rate (56 mg/m2/min) and nonoxidative glucose metabolism (18 mg/m2/min) were comparable to those in the control group (Fig. 1) . The insulin-stimulated glucose disposal rate was severely decreased in proband 1 and to a lesser degree in both parents (proband 1, 146 mg/m2/min; mother, 308 mg/m2/min; father, 247 mg/m2/min; control group, 381±32 mg/m2/min) primarily owing to a decrease in nonoxidative glucose metabolism (proband 1, 42 mg/m2/min; mother, 183 mg/m2/min; father, 91 mg/m2/min; control group, 227±24 mg/m2/min) (Fig. 1) . Table I ) during the basal period and after 4 h of hyperinsulinemia (2 mU kg-' min-').
Basal oxidative and nonoxidative glucose metabolism was increased in the proband when compared with both his parents and the control group. During insulin infusion, however, total glucose disposal rate was severely decreased in the proband and to a lesser extent in his parents, when compared with the control group. This decrease was mainly due to a decrease in nonoxidative glucose metabolism. 30±5 mg/m2/min). During insulin infusion, lipid oxidation decreased in all participants. However, the suppression of lipid oxidation during insulin infusion was clearly impaired in proband 1 (22 mg/m2/min) and to a lesser extent in the mother (9 mg/m2/min) when compared with the father (1 mg/m2/min) and the control group (0.4±5 mg/m2/min).
Hepatic glucose output (HGO) was increased in the basal state in proband 1 (104 mg/m2/min) when compared with both parents and the control group (mother, 71 mg/m2/min; father, 75 mg/m2/min; control group, 75±4 mg/m2/min). During insulin infusion, HGO was fully suppressed in the parents and the control group (mother, -22 mg/m2/min; father, -75 mg/m2/ min; control group, -87±12 mg/m2/min). However, in proband 1, HGO remained increased, suggesting insulin resistance at the hepatic level (70 mg/m2/min).
Insulin receptor binding and kinase activity. The effect of an increase in serum insulin concentration during the euglycemic hyperinsulinemic clamp on insulin receptor kinase (IRK) activity was measured in muscle biopsies from the parents and four of the control subjects (no analysis was done in the oldest boy with CFTDM because an inadequate amount of muscle tissue was available for analysis) using a microtiter well assay system (Fig. 2) . In the father the increase in IRK activity was only 50% of that in the control subjects despite a more than twofold higher level of serum insulin. Activation of IRK is almost linearly dependent of the insulin concentration in this concentration range ( GS mRNA. The abundance of the specific n GS mRNA relative to rabbit P-globin mRNA (exwas assessed using PCR technique. The relative mRNA showed a two-to fourfold variation amo pants. However, the levels of GS-specific mRNA (basal biopsy only) and the parents (both bas biopsies) were comparable to the levels found group, although a tendency to lower levels was se I and the father (Table III) .
GS-immunoreactive protein leveL The amouni noreactivity in homogenates from vastus laterali quantitated by immunoblotting using anti-peptidc cific for GS. In all participants a dominant band identified for GS-immunoreactive protein (Fig. 3 ship of insulin action and muscle anabolism, and it has been hypothesized that the degree of muscle wasting in MD is somehow related to the severity of insulin resistance (28) .
In our study both glucose-tolerant parents to the CFTDM patients, in particular their father, showed insulin resistance during the clamp when compared with a control group, and interestingly, fasting hyperinsulinemia was also found in the father. The strikingly increased serum insulin levels in the CFTDM patients could not be explained by increased levels of proinsulin, since the two-site immunoassay used is highly specific and does not measure human proinsulin. This was further confirmed by measuring serum proinsulin levels during the OGTJ: the levels of serum proinsulin were increased in the two boys when compared with both parents and their unaffected brother, probably reflecting a constant stress on pancreatic /3 cell function. However, the two probands did not have an increased proportion of proinsulin to insulin compared with the unaffected brother, mother, and father.
We used the euglycemic hyperinsulinemic clamp technique in combination with indirect calorimetry and infusion of tritiated glucose to compare basal and insulin-stimulated glucose metabolism and lipid oxidation in the oldest boy affected with CFT'DM, his parents, and a control group. A 62% decrease in insulin-stimulated total glucose disposal rate in the boy with CFTDM was demonstrated when compared with the control group, and this decrease was, under the chosen experimental conditions, accounted for predominantly by a severely decreased nonoxidative glucose metabolism and to a lesser degree by a decreased oxidative glucose metabolism.
None of the probands had acanthosis nigricans, a clinical feature frequently associated with congenital syndromes of severe insulin resistance (25) . They both had growth retardation with severe muscle hypotrophy, a potential consequence of impaired insulin action on muscle cell differentiation and growth. The moderately insulin-resistant but glucose-tolerant father also had short stature.
CFT'DM is a previously undescribed form of severe insulin resistance and diabetes that may be related to genetic defects at one or more steps in the cellular action of insulin. Insulin initiates its pleiotropic cellular effects by binding to the a subunit of its tetrameric plasma membrane receptor, which in turn results in a rapid autophosphorylation of specific tyrosine residues on the /3 subunit (29) . This activation further stimulates the tyrosine kinase activity of the receptor toward other protein substrates in the cascade of insulin action. Using a microtiter well assay system to measure in vivo insulin activation of the IRK, we found that the kinase activity was severely decreased in the father of the CFTDM patients when compared with both the mother and the control subjects. No analysis of IRK activity was done for any of the patients with CFTDM because of an inadequate amount of muscle tissue. However, the demonstration of a > 70% decrease in IRK activity in the father, who was characterized as having hyperinsulinemia in the fasting state and during the clamp, increased insulin response to an OGTT, and insulin resistance, made it likely that a defect or defects exist in insulin receptor function with or without mutations in the insulin receptor gene also in the patients with CFTDM. In fact, preliminary studies of the molecular genetics of this family have revealed that the affected brothers have inherited a mutation in the tyrosine kinase domain of the insulin receptor from their father and a deletion of exon 17 in part of their insulin receptor mRNA from their mother (30) . Additionally, the two affected brothers have inherited a heterozygous missense mutation at codon 513 (alanine --proline) in insulin receptor substrate-l from their father (30) .
Under clamp conditions of euglycemia and hyperinsulinemia, insulin resistance is a prominent feature of many patients with NIDDM (31). Skeletal muscle has been shown to be the quantitatively dominant tissue of insulin resistance under these experimental conditions (24) , and nonoxidative glucose metabolism, which reflects primarily muscle glycogen synthesis (32) , represents the major intracellular pathway responsible for the insulin insensitivity (31, 33) . Several abnormalities in the activation of muscle GS, which is a key enzyme in the glycogen synthesis pathway, have been reported in studies of patients with NIDDM. Insulin-stimulated glucose disposal rate was severely decreased in proband 1 and to a lesser degree in the parents when compared with the control group. The decrease was primarily due to a decrease in nonoxidative glucose metabolism, and in proband 1 it was paralleled by lower basal levels of muscle-specific GS mRNA, immunoreactive GS protein, GS activity, and impaired allosteric activation of GS by G6P when compared with the control group. Whether the impairment in expression of the GS gene is a primary phenomenon due to structural defects in GS itself or is secondary to the genetic abnormalities in the insulin receptor or insulin receptor substrate-1 or in other key enzymes in the signaling pathway from the receptor to GS can at present only be speculated. Alternatively, the concomitant hormonal and metabolic disturbances might cause the alterations of GS expression. An abnormality anywhere in the complex pathway of GS activation could change the balance of GS from the active dephosphorylated form toward the less active phosphorylated form, thus contributing to insulin resistance (34, 35) .
From studies of nondiabetic men, it has been suggested that myocyte size and myocyte fiber type may play important roles in the regulation of insulin sensitivity (36) . A positive correlation was found between peripheral glucose uptake and the percentage of oxidative type 1 muscle fibers. Oxidative type 1 fibers are slow-twitch fibers known to be very sensitive to insulin, whereas type 2B slow-twitch fibers are less sensitive (36) . Moreover, it has been demonstrated that insulin-stimulated glucose disposal rate is significantly increased in athletes compared with sedentary control subjects (37) . The same athletes were characterized as having a 40% higher relative area of type 1 fibers in vastus lateralis muscle and a 75% lower area of type 2B fibers when compared with control subjects. Furthermore, a negative correlation between type 2B muscle fibers and insulinstimulated glucose disposal rate was also demonstrated (37) . CFTDM patients have an excess of small slow-twitch oxidative type 1 muscle fibers and normal or hypertrophied fast-twitch glycolytic type 2A or 2B fibers. Whether the distribution and type of muscle fibers in the CFTDM patients are primary or secondary to the insulin resistance as demonstrated in our patients is at present unknown.
